GlassScriptPhysician profile
Randi E Rubenzik
NPI 1588612964
$2,460.88
in general payments reported to CMS, 2019-2025
25 companies · $638 in 2025
The $638 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $765 · 2020: $175 · 2021: $244 · 2022: $55.09 · 2023: $66.77 · 2024: $518 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,207 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,206.77 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $481.56 | 2019-2025 | Skyrizi |
| Genzyme Corporation | $301.52 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $195.53 | 2023-2025 | Zoryve |
| Pfizer INC. | $167.78 | 2019-2025 | |
| Lilly USA, LLC | $165.41 | 2019-2025 | Taltz, Ebglyss |
| Medtronic Vascular, INC. | $163.09 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $119.88 | 2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $112.24 | 2019 | |
| Organon LLC | $107.74 | 2025 | Vtama |
| Genentech USA, INC. | $80.45 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $66.28 | 2019-2022 | |
| Amgen INC. | $60.37 | 2019-2025 | Otezla, Otezla |
| Ucb, INC. | $58.54 | 2025 | Bimzelx |
| Janssen Biotech, INC. | $52.23 | 2021-2025 | Tremfya |
| Botanix Sb INC | $49.73 | 2025 | Sofdra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $49.41 | 2021-2024 | |
| Almirall LLC | $34.32 | 2019-2024 | Klisyri |
| Dermira, INC. | $34.27 | 2019 | |
| Dermavant Sciences, INC. | $33.09 | 2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $33.04 | 2024 | Sotyktu |
| Leo Pharma INC. | $23.81 | 2025 | Anzupgo |
| Biofrontera INC. | $21.11 | 2021 | |
| Mayne Pharma Commercial LLC | $18.50 | 2019 | |
| Incyte Corporation | $18.16 | 2025 | Opzelura |
| Dusa Pharmaceuticals, INC. | $12.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randi Rubenzik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.